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Abstract
Objectives: To measure the feasibility and effectiveness of interventions to increase cervical screening uptake amongst young
women.
Methods: A two-phase cluster randomized trial conducted in general practices in the NHS Cervical Screening Programme. In
Phase 1, women in practices randomized to intervention due for their first invitation to cervical screening received a pre-invitation
leaflet and, separately, access to online booking. In Phase 2, non-attenders at six months were randomized to one of: vaginal self-
sample kits sent unrequested or offered; timed appointments; nurse navigator; or the choice between nurse navigator or self-
sample kits. Primary outcome was uplift in intervention vs. control practices, at 3 and 12 months post invitation.
Results: Phase 1 randomized 20,879 women. Neither pre-invitation leaflet nor online booking increased screening uptake by
three months (18.8% pre-invitation leaflet vs. 19.2% control and 17.8% online booking vs. 17.2% control). Uptake was higher
amongst human papillomavirus vaccinees at three months (OR 2.07, 95% CI 1.69–2.53, p< 0.001). Phase 2 randomized 10,126
non-attenders, with 32–34 clusters for each intervention and 100 clusters as controls. Sending self-sample kits increased uptake at
12 months (OR 1.51, 95% CI 1.20–1.91, p¼ 0.001), as did timed appointments (OR 1.41, 95% CI 1.14–1.74, p¼ 0.001). The offer
of a nurse navigator, a self-sample kits on request, and choice between timed appointments and nurse navigator were ineffective.
Conclusions: Amongst non-attenders, self-sample kits sent and timed appointments achieved an uplift in screening over the
short term; longer term impact is less certain. Prior human papillomavirus vaccination was associated with increased screening
uptake.
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Introduction
Eﬀective cervical screening requires high population cover-
age, but in recent years uptake amongst young women in
England has been dropping, particularly for those receiv-
ing their ﬁrst invitation to screening.1 Since 2004, ﬁve-year
coverage amongst 25–29 year olds nationally has fallen
from 72% to 66%.1 In Manchester, initial uptake is only
around 25%, prior to a standard reminder at three
months.2 A recent systematic review of interventions to
increase coverage in young women found some eﬀect
from reminders, but there was a need to evaluate interven-
tions designed to overcome other potential barriers.3 The
NHS Cervical Screening Programme in England issues
invitations from age 25, which are accompanied by a
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lengthy factual leaﬂet designed to educate, rather than
motivate participation. Pre-notiﬁcation for colorectal
screening has been associated with a small but signiﬁcant
increase in uptake in both Australia4 and Scotland.5 A
‘pre-invitation leaﬂet’ (PIL) to prepare young women to
engage more fully would be consistent with the trans-
theoretical model of tailoring interventions in line with
the stages of progression from non-engagement, towards
readiness for an activity such as screening.6 We designed a
PIL7 which covered issues that had arisen in focus group
discussions. Ease of access is important for realizing good
medical outcomes,8 and we hypothesized that a facility to
book an appointment for a cervical screen online would ﬁt
better with the current habits of young women.
The initial aim of this randomized trial was to deter-
mine whether one or both of these strategies would
increase uptake of cervical screening within six months.
The second aim of the trial was to evaluate the comple-
mentary approach of intervening when women have failed
to attend by six months. These women comprise a group
who have chosen not attend for a variety of reasons,
which have been documented in a qualitative study as
fear, embarrassment, and inconvenience,9 though younger
women in the same study raised the issue of practical bar-
riers. Our hypothesis was that for these women, there are
diﬀerent reasons for non-attendance.
Vaginal self-sampling for high-risk human papilloma-
virus (HPV) (HR-HPV) testing now oﬀers an eﬀective
means of primary cervical screening and provides a con-
venient and possibly less embarrassing means of screen-
ing.10 The detection of HR-HPV does not require cell
morphology, so the need for a formal cervical cytology
sample can be restricted to the minority of around 10%
who test HR-HPV positive. Self-sampling for non-
attenders has been evaluated with mixed results, uptake
varying between 8.7 and 39%,11 with the oﬀer of a self-
sampling kit (SSK) less eﬀective than sending SSK to all
non-attenders. Timed appointments (TA) are another
means that has been used to reduce the inconvenience of
having to book a screening appointment, with some evi-
dence that this is eﬀective.12,13 ‘Nurse navigators’ (NNs)
have been evaluated in colorectal cancer to help women
through the screening pathway.14 We also wished to
evaluate whether being able to choose between an NN
and the oﬀer of being sent an SSK would engage some
women.
We undertook a cluster randomized trial amongst
women who were receiving their initial invitation to cer-
vical screening, as a feasible means of randomizing women
who could not be directly approached on an individual
basis by the investigators. Interventions were allocated by
cluster, and concealed from the control practices. The trial
was undertaken in Greater Manchester, England, where
screening begins aged 25, and in Grampian, Scotland, in
order to include a cohort of women who had been
oﬀered vaccination in the catch-up campaign, and who
entered the screening programme aged 20. The primary
outcome was screening uptake amongst invited women.
Methods
Phase 1 evaluated a PIL and the opportunity to book
online; Phase 2 evaluated TA, SSK sent, SSK oﬀered,
and an NN, amongst the women who had failed to
attend for screening during Phase 1. Women were told
how to make contact with the NN, who could provide
information and support. SSK sent or oﬀered comprised
either the Delphi lavage or the Rovers Evalyn Brush,
which were used to obtain a vaginal sample, and packa-
ging in which to return the sample compliant with trans-
port regulation UN3373 for Category 3 Biological
Substances.
Phase 1
During Phase 1, we evaluated the PIL and the opportun-
ity to book online. Eligible women in three Greater
Manchester Primary Care Trusts (PCTs), Traﬀord,
Salford, and Manchester in North West England were
those aged 24 years and 6 months, due to receive their
ﬁrst invitation for cervical screening in three months. A
total of 276 general practices were cluster randomized for
women in a ratio of 1:1 to receive a PIL prior to their
standard invitation. Women in control practices did not
receive a PIL. Clusters were eligible if the general prac-
tice engaged in cervical screening as part of the NHS
national programme. Eligible women in Grampian were
those aged 20 who were due to receive their ﬁrst cervical
screening invitations in three months. General practices
in Grampian were similarly randomized to receive or not
receive a PIL. The PIL was sent to women in Greater
Manchester by LaSCA (the screening agency which
maintained the population-based register for the NHS
Cervical Screening Programme) prior to the standard
invitation, also sent by LaSCA. In Grampian, a list of
eligible women was extracted from the Scottish Cervical
Call Recall System (SCCRS), and these women were sent
a PIL by the trial oﬃce. Interventions were sent to eli-
gible women between April 2012 and December 2013.
Online booking for cervical screening had not been avail-
able previously, so a new facility, which could only be
made available in the Manchester PCT, was required to
enable access to an online appointment system, and this
was established in the Contraception and Sexual Health
Service. All practices in the Manchester PCT only were
also randomized to provide women access to online
booking at Sexual Health clinics. Women received a
letter explaining how appointments were available at sev-
eral community-based clinics, where appointments were
oﬀered at diﬀerent times of each day. Vaccination status
of randomized women in Scotland was obtained from
SCCRS, which has linked vaccination data.
Phase 2
Women became eligible for Phase 2 if they had not been
screened six months after the initial invitation. A total of
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276 general practices in Greater Manchester and
Grampian which had participated in Phase 1 were re-ran-
domized to one of ﬁve diﬀerent interventions, with each
intervention in a ratio of 1:3 control practices. This
included TA, oﬀer of NN, SSK sent to all (SSK sent),
SSK sent on request (SSK oﬀer), and a choice between
the oﬀer of an NN and an SSK (choice). Women were told
that the NN could provide information and support and
were given contact details. Each of these interventions had
been piloted15 amongst a diﬀerent cohort of similarly aged
non-attenders, and all but oﬀer of NN alone had been
found to be feasible to implement, practicable, and
taken up by a least 5% of those oﬀered. Two self-sampling
devices were piloted; the Delphi lavage or Evalyn brush
(Rovers Medical Devices BV, Oss, the Netherlands) and
neither was preferred over the other. Both were therefore
used, with women being sent either one or the other.
Women who had not been recorded as having been
screened were sent the intervention oﬀer by the NHS
Screening Agency. TA were made available by all rando-
mized general practices.
The investigators provided the Screening Agency in
Greater Manchester with SSKs and these and other inter-
ventions were mailed to women on a weekly basis. In
Grampian, the company that maintains the SCCRS
(ATOS) provided the local investigator with a weekly
list of women eligible for the trial, and the interventions
were mailed by the trial team in Aberdeen. Because of the
six-week period required to identify women who were eli-
gible and then send the appropriate intervention, the mail-
ing for Phase 2 actually took place 7.5 months rather than
six months following the initial invitation. The primary
end points for screening uptake were 3 and 12 months
following the invitation for Phase 1 and Phase 2,
respectively.
Ethical approval for the trial was provided by
NRES Committee North West – Greater Manchester
North (Ref: 11/NW/0624). Both Phase 1 and Phase 2
of the STRATEGIC trial were registered
ISRCTN52303479.
Randomization
There were 276 and 267 practices included in Phases 1 and
2, respectively. In both phases, practices were allocated to
intervention using the minimization algorithm for cluster
randomized trials described by Raab and Butcher,16 bal-
ancing for practice size and screening uptake. For each
PCT, 10,000 possible allocations of practices were gener-
ated and an imbalance metric between trial arms calcu-
lated for each. From these allocations, the ﬁfth centile of
imbalance distribution was selected, as lower values of the
metric represented better balance. This was implemented
in the statistical package Stata17 by the trial statistician
(CR). York Trials Unit then randomized the interventions
to the balanced trial arms that had been generated
for each PCT with the practices names in each arm
concealed.
Sample size
Routine data from the screening services had suggested
that an average of 40 women per practice would become
eligible over a 12-month period, with an expected response
to ﬁrst invitation of about 30%. Jensen et al.18 estimated
an intra-cluster correlation (ICC) of 0.0265 for a similar
outcome. Based on these assumptions, a trial with 100
practices randomized to PIL (4000 women) and 100 con-
trol practices would have a power of 91% to detect an
absolute uplift of 5% by three months. The online book-
ing intervention was to be tested in approximately 100
practices (Manchester PCT only). With 50 practices each
(2000 women) randomized either to online booking or
control, this would have power of 93% to detect a 7.5%
improvement in attendance. With 30 practices per inter-
vention arm and 100 control practices, Phase 2 had 80%
power to detect an increase in uptake from 10% expected
amongst controls, and 20% following interventions. This
would assume that 50% of the cohort from Phase 1 would
enter Phase 2, with an ICC4 0.07, a ﬁve comparison
Bonferroni corrected signiﬁcance level, and an adjustment
for cluster size variation.
Statistical method
Statistical analysis was based on intention to treat prin-
ciples according to the women’s practice at the time of ﬁrst
invitation. Primary outcome data were complete, as they
relied on the record of a screening test result by three and
six months for Phase 1, and 12 and 18 months for Phase 2,
following the routine invitation. Odds ratios (OR) and
95% conﬁdence intervals (95% CI) with robust standard
errors, represented intervention vs. control, and were
adjusted for practice uptake rate, locality, and clustering
in a logistic Generalized Estimating Equations model.19
To aid interpretation of the treatment eﬀects, the marginal
diﬀerence in the uptake rate, which is the diﬀerence in
uptake between the intervention and control averaged
across covariates, calculated from the logistic model, is
reported. Key moderators of interventions: location
(Greater Manchester vs. Grampian), vaccination status
(none, incomplete, complete, missing) in Grampian only,
and prior Phase 1 interventions for Phase 2, were identi-
ﬁed a priori and performed as interactions. Consistent
with the power calculation in Phase 2, a multiple compari-
son Bonferroni correction is applied with a signiﬁcant
level of 1% in place of 5%. Analysis was performed in
Stata v13.17
Data collection
The LaSCA and SCCRS supplied screening uptake data
based on a cytology sample being received for individual
women from control and intervention practices. HPV vac-
cine status and screening outcome data were extracted
from the SCCRS system. SCCRS links to the Scottish
Immunization Recall System, which records data
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including type of vaccine, number of doses, and dates on
which doses were administered.
Results
Phase 1
The ﬂow of women through the trial, together with
number of practices, is shown in the CONSORT diagram
(Figure 1). In Phase 1, 20,879 women in 276 practices were
allocated by cluster randomization between April 2012
and December 2013. Figure 2(a) shows a Kaplan Meier
plot of the cumulative uptake over time for PIL and con-
trol groups. There was an early increase in uptake for the
PIL group immediately post invitation, but any small dif-
ference had dissipated by three months. Table 1 shows the
frequency of uptake by intervention group, and the
adjusted OR of being screened for each intervention at
three and six months. The OR adjusted for baseline
uptake compared with control was 0.97 (95% CI 0.88–
1.06, p¼ 0.485) at three months and 1.01 (95% CI 0.93–
1.11, p¼ 0.747) at six months.
As shown in Figure 2(b) and Table 1, the eﬀect of
online booking at the three-month time point was min-
imal. The adjusted OR for online booking at three months
was not signiﬁcant (Adj. OR¼ 1.02; 95% CI 0.86–1.20
p¼ 0.80). The marginal increase in uptake was 0.30%
(95% CI 2.02, 2.61) at three months. Table 1 and
Figure 2(b) suggest a slight increase in uptake for online
booking by six months, but this was not statistically sig-
niﬁcant (Adj. OR¼ 1.10; 95% CI 0.94–1.28, p¼ 0.24). At
six months, the marginal increase in uptake was 1.83%
(95% CI 1.23–4.89). Of 199 women who booked an
appointment online, only 127 (63.8%) actually attended
that appointment. The remainder either did not attend or
cancelled. When the logistic regression model was ﬁtted,
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Figure 1. CONSORT diagram for the STRATEGIC trial.
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there was no evidence of an interaction between the eﬀect
of the PIL and that of online booking (p¼ 0.604).
Table 2 demonstrates the relationship between vaccin-
ation status and uptake in the Grampian region and com-
pares Grampian with Greater Manchester. Within the
Grampian cohort, vaccination status was associated with
signiﬁcant diﬀerences in screening uptake. Compared with
non-vaccinated women in whom uptake at three and six
months was only 11.0% and 18.2%, respectively, in fully
vaccinated women the corresponding uptake was 23.7%
and 40.1%; OR 2.07 (95% CI 1.70–2.53) and 2.57 (95%
CI 2.20–3.00). Women whose status was ‘vaccination
incomplete’ had lower uptake than fully vaccinated
women, but better uptake than non-vaccinated women.
Diﬀerences associated with vaccination status were statis-
tically signiﬁcant at both three months (p¼ 0.032 and
<0.001) and six months (p4 0.001 and <0.001) for
incomplete and full vaccination, respectively. These
trends were seen in both the pre-leaﬂet and control arms.
Phase 2
After exclusions due to a three-month delay in starting
Phase 2, and changes of address making women uncon-
tactable, 10,126 women were cluster randomized between
April 2013 and November 2014 (Manchester running six
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Figure 2. (a) Kaplan Meier Plot showing Time to Test for pre-leaflet and online booking groups and (b) Kaplan Meier Plot showing Time to
Test for online booking groups – Manchester PCT only.
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months ahead of Grampian in Phase 2), with practices
stratiﬁed by whether or not they had the PIL intervention
in Phase 1. Nine practices were lost: seven due to all eli-
gible women having been screened, and two where
remaining eligible women had moved. This left 32–34
practices for each intervention and 101 control practices.
The numbers of practices and women are shown in the
CONSORT diagram (Figure 1). The median duration of
follow-up without attendance was 24.2 months, and the
minimum was 17.8 months, i.e. within six days of the 18
month outcome. The median time to attendance amongst
those screened was 11.9 months (interquartile range 8.9–
16.7), which reﬂected the continuous rate of uptake over
time in Phase 1. The rate of uptake following each of the
interventions is shown in Figure 3(a) and (b). The type of
screening test recorded for women at the 12 and 18 month
time points is shown in Table 3, according to the inter-
vention oﬀered. Amongst the control and interventions
other than SSKs, only one or two had HPV tests at 12
and 18 months, respectively, in line with the standard
Table 2. Screening uptake at three and six months post call by vaccinations status (Grampian only) and region.
Vaccination status (Grampian region)
Follow-up Status Percent (Freq./n) ORa 95% CI P value ICCb
Three month None 11.03 (145/1315) – – – 0.015
Incomplete 18.27 (59/323) 1.404 0.103, 1.914 0.032
Full 23.65 (781/3307) 2.074 1.698, 2.534 <0.001
Missing 9.84 (6/61) 0.760 0.402, 1.438 0.399
Six month None 18.17 (239/1315) – – – 0.007
Incomplete 30.03 (97/323) 1.555 1.213, 1.992 0.001
Full 40.13 (1325/3307) 2.571 2.205, 2.999 <0.001
Missing 19.67 (12/61) 0.974 0.541, 1.754 0.930
Region
Follow-up Location Percent (Freq./n) ORa 95% CI P value ICCb
Three month Greater Manchester 18.79 (2981/15,873) – – – 0.043
Grampian 19.82 (991/5006) 1.169 1.030, 1.326 0.016
Six month Greater Manchester 30.08 (4774/15,873) – – – 0.066
Grampian 33.46 (1673/5006) 1.275 1.133, 1.435 <0.001
OR: odds ratios; ICC: intra-cluster correlation.
aOdds ratio adjusted for intervention and baseline practice rate.
bIntra-cluster correlation coefficient estimate of model.
Table 1. Screening uptake rate at three and six months post call for each intervention group.
Pre-leaflet intervention (all sites)
Control Pre-leaflet Total
Follow-up post call Percent (freq./n) Percent (freq./n) Percent (freq./n) ORa 95% CI P value ICCb
Three months 19.22% (2002/10,418) 18.83% (1970/10,461) 19.02% (3972/20,879) 0.967 (0.879, 1.062) 0.485 0.0099
Six months 30.63% (3191/10,418) 31.13% (3256/10,461) 30.88% (6447/20,879) 1.014 (0.928, 1.109) 0.747 0.0157
Online booking intervention (Manchester PCT)
Control Online booking Total
Follow-up post call Percent (freq./n) Percent (freq./n) Percent (freq./n) ORc 95% CI P value ICCb
Three months 17.24% (770/4467) 17.77% (936/5267) 17.53% (1706/9734) 1.021 (0.869,1.200) 0.802 0.0090
Six months 26.64% (1190/4467) 28.82% (1518/5267) 27.82% (2708/9734) 1.097 (0.939,1.282) 0.242 0.0194
OR: odds ratios; ICC: intra-cluster correlation; PCT: Primary Care Trust.
aOdds ratio adjusted for site and baseline uptake rate.
bIntra-cluster correlation coefficient estimated by model.
cOdds ratio adjusted for baseline uptake rate.
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screen being cytology. Amongst women to whom SSKs
were sent, 243/1141 (21.3%) and 342/1141 (30.0%) had
been screened at 12 and 18 months, respectively. Of
those who had been screened, only 84/243 (34.6%) and
93/342 (27.2%) were screened initially by HPV testing,
with the large majority attending their practice for cytol-
ogy. A similar pattern was seen amongst women who were
oﬀered an SSK on request, with only 19/209 (9.1%) and
19/333 (5.7%) who were screened at 12 and 18 months,
respectively, actually returning a self-obtained sample.
This indicates that an SSK being sent prompted most
women who were screened to attend in person.
The uptake of screening amongst women in Phase 2 by
the diﬀerent interventions is shown in Table 4, at the 12-
and 18-month time points post invitation. The results are
again expressed as an OR compared with controls, with
adjustment for the baseline attendance by practice and
region. Control uptake was 16.2% and 27.1% at 12 and
18 months, respectively. Only SSK sent and TA showed a
signiﬁcantly increased uptake at the primary endpoint of
12 months post invitation; 21.3% and 19.8%, respectively,
OR 1.51 (95% CI 1.20–1.91) and 1.41 (95% CI 1.14–1.74).
By 18 months, the control uptake had risen to 27.1%, and
while SSK sent remained signiﬁcantly greater at 30% (OR
1.29; 95% CI 1.06–1.57), TA no longer showed signiﬁ-
cantly increased uptake, and the oﬀer of an NN showed
signiﬁcantly reduced uptake.
Discussion
This trial has revealed no signiﬁcant diﬀerence in cervical
screening uptake over six months amongst women
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receiving their ﬁrst invitation, either as a result of a PIL or
the oﬀer to book a screening test online. Amongst non-
attenders at six months, SSK sent to all eligible women,
and TA each showed a statistically signiﬁcant uplift in
screening compared with controls at the time point 12
months following initial invitation, though by 18 months
only SSK sent continued to exert an increase in screening
uptake. There was no evidence of an interaction between
the eﬀect of the PIL and that of online booking. In both
Phases 1 and 2, there was a steady increase in uptake of
screening over time in the control arms, from around 20%
at three months to 30% at six months, and of the non-
attenders at six months, a further 16% had been screened
by 12 months and 27% by 18 months in the control arm.
This applied equally in both intervention and control
practices, both in Greater Manchester and Grampian.
We are not aware of any external measure to inﬂuence
uptake during the trial.
The lack of impact on behaviour exerted by the PIL is
not easily interpreted. In behavioural change, progress
from pre-contemplation to the action stage depends on
decisional balance.20 Prochaska21 speculated that only
about 50% of a target group at the pre-contemplation
stage intends to take action in the near future, as the nega-
tive aspects of the intervention strongly outweigh the posi-
tives. Young women express many concerns about
Table 3. Type of Test utilized by the participant split by intervention and HPV result at 12 months and 18 months.a
Follow-up Phase 2 intervention No test
Single test Both tests
Total tested TotalHPV only
Cytology
only HPV first Cytology first
12 Months Control 3169 1 612 – – 613 3782
Self-samp. sent 898 52 158 32 1 243 1141
Self-samp. off. 1081 12 190 7 – 209 1290
Nurse nav. 861 – 145 1 – 146 1007
Timed app. 1306 – 323 – – 323 1629
Choice 1037 5 233 2 – 240 1277
Total 8352 70 1661 42 1 1774 10,126
18 Months Control 2756 1 1025 – – 1026 3782
Self-samp. sent 799 59 248 34 1 342 1141
Self-samp. off. 957 12 314 7 – 333 1290
Nurse nav. 777 – 229 1 – 230 1007
Timed app. 1157 1 471 – – 472 1629
Choice 892 5 378 2 – 385 1277
Total 7338 78 2665 44 1 2788 10,126
Single test (%) Both tests (%)
Follow-up Phase 2 intervention No test (%) HPV only
Cytology
only HPV first Cytology first
Total tested
(%) Total
12 Months Control 3169(83.8) 1(0.0) 612(16.2) – – 613(16.2) 3782
Self-samp. sent 898(78.7) 52(4.6) 158(13.8) 32(2.8) 1(0.1) 243(21.3) 1141
Self-samp. off. 1081(83.8) 12(0.9) 190(14.7) 7(0.5) – 209(16.2) 1290
Nurse nav. 861(85.5) – 145(14.4) 1(0.1) – 146(14.5) 1007
Timed app. 1306(80.2) – 323(19.8) – – 323(19.8) 1629
Choice 1037(81.2) 5(0.4) 233(18.2) 2(0.2) – 240(18.8) 1277
Total 8352(82.5) 70(0.7) 1661(16.4) 42(0.4) 1(0.0) 1774(17.5) 10,126
18 Months Control 2756(72.9) 1(0.0) 1025(27.1) – – 1026(27.1) 3782
Self-samp. sent 799(70.0) 59(5.2) 248(21.7) 34(3.0) 1(0.1) 342(30.0) 1141
Self-samp. off. 957(74.2) 12(0.9) 314(24.3) 7(0.5) – 333(25.8) 1290
Nurse nav. 777(77.2) – 229(22.7) 1(0.1) – 230(22.8) 1007
Timed app. 1157(71.0) 1(0.1) 471(28.9) – – 472(29.0) 1629
Choice 892(69.9) 5(0.4) 378(29.6) 2(0.2) – 385(30.2) 1277
Total 7338(72.5) 78(0.8) 2665(26.3) 44(0.4) 1(0.0) 2788(27.5) 10,126
HPV: human papillomavirus.
aSixty-two women were within six days of 18 months follow-up and excluding these produced no change in the effect estimates or significance levels reported in
Table 4.
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cervical screening3,7 and do not feel at risk of cancer. The
PIL was probably insuﬃcient to allay these negatives.
Online booking failed to achieve a statistically signiﬁ-
cant increase in screening uptake, and of those who made
an online appointment, 40% failed to attend the planned
appointment. It is possible that if this facility were made
more freely available in general practices it could prove
popular as an eﬃcient means of gaining an appointment,
although those who failed to attend an appointment, des-
pite a text reminder, could represent a waste of resources.
The trial was adequately powered, exceeding the target
sample size in both numbers of clusters and number of
women per cluster, and the ICC for general practitioner
(GP) practices was slightly smaller than that used for the
sample size calculation.
The diﬀerential uptake of screening between HPV-vac-
cinated and non-vaccinated young Scottish women was
striking and suggests that vaccination may have increased
awareness of the relevance of screening. The reliability of
these data is ensured by linkage between SCCRS and the
Scottish Immunization Record System. Similar ﬁndings
have been reported recently from Sweden22 and
Scotland.23 By contrast, a study in Victoria, Australia24
found that participation in cervical screening was lower in
20–24 year olds who had been vaccinated, compared with
unvaccinated women, with uptake rates not too dissimilar
from our data. Our ﬁndings are encouraging and under-
line the importance of synergy between primary and
secondary cervical cancer prevention, but the uptake
rate at six months of only 18% amongst unvaccinated
women in Grampian is a major concern, as this group
may also have lifestyle factors that are associated with
an increased risk of cervical cancer. This is worthy of
more detailed research.
It might have been expected that during Phase 2 a
smaller proportion of controls than seen in Phase 1 con-
trols would have been screened, but in fact, rather than
reacting promptly to an invitation, women made a deci-
sion to be screened over a period of 18 months, by which
time, 27% of non-attenders at six months had been
screened. This pattern of a delay in deciding to be
screened, would appear to reﬂect a feeling that cervical
screening is important but not urgent, and over a variable
period of time a signiﬁcation proportion of women get
around to attending. This suggests that an intervention
for non-attenders could be withheld until 18 months,
after which time attendance appeared to plateau. The
second observation from the Phase 2 results is that
SSKs being sent to all non-attenders was the most eﬀective
intervention. It is striking that the majority of those
screened following SSK being sent, whether requested or
sent unrequested, were actually screened by means of
cytology and not HPV testing. The SSK appears to have
‘nudged’ women to go for cytology, suggesting that they
had a positive attitude to screening (referred to as inclined
abstainers9), but rather than using the SSK, preferred to
Table 4. Phase 2 attendance (%) of tests occurring within 12 months and 18 months since standard invite.
Phase 2 intervention Attendance percent (freq/n) ORa 95% CI P valueb ICCc
12 months (4.5 months since Phase 2 intervention)
Control 16.2 (613/3782) – – – 0.0083
Self-sample sent 21.3 (243/1141) 1.512 1.197, 1.910 0.001
Self-sample off. 16.2 (209/1290) 1.074 0.871, 1.325 0.505
Nurse navigator 14.5 (146/1007) 0.887 0.670, 1.174 0.401
Timed appt. 19.8 (323/1629) 1.408 1.141, 1.738 0.001
Choice 18.8 (240/1277) 1.091 0.864, 1.378 0.466
Total 17.5 (1774/10,126) – – <0.001d –
18 months (10.5 months since Phase 2 intervention)
Control 27.1 (1026/3782) 0.0211
Self-sample sent 30.0 (342/1141) 1.286 1.056, 1.567 0.012
Self-sample off. 25.8 (333/1290) 1.056 0.884, 1.262 0.548
Nurse navigator 22.8 (230/1007) 0.799 0.642, 0.994 0.044
Timed appt. 29.0 (472/1629) 1.191 0.975, 1.456 0.087
Choice 30.2 (385/1277) 1.058 0.869, 1.289 0.573
Total 27.5 (2788/10,126) – – 0.008d –
OR: odds ratios; ICC: intra-cluster correlation.
aOR Adjusted Odds Ratio associated with the change in odds of attendance occurring within intervention compared to control, adjusted for
practice attendance rate and PCT region.
bComparison of each intervention against control. To maintain an overall 5% level, these can be interpreted with a 1% significance level.
cIntra-cluster correlation coefficient indicating level of agreement between GP clusters as defined by the logistic GEE model.
dOverall 25 p value comparing all trial arms in Phase 2.
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be screened by a health professional. Further insight is
required as to why women exerted this preference, but it
may be related to a lack of conﬁdence in obtaining a self-
sample. Whether the actual kit represented a more con-
vincing ‘nudge’ than another reminder is unknown. By
contrast, SSK oﬀered was not eﬀective, a disparity
which was also found in a recent meta-analysis of 16 ran-
domized trials, some sending and others oﬀering SSKs.11
This meta-analysis also reported diﬀerences between ‘per
protocol’ (the return of self-samples), and ‘intention to
treat’ (the return of self-samples plus attendance for cytol-
ogy), but these were not as large as seen in our study. In
terms of the incremental uptake, SSK sent and TA
achieved around 5% and 35%, respectively, compared
with controls at 12 months, but as this was the proportion
of non-attenders, the uplift for the screened population as
a whole was nearer 2%–3% in absolute terms. The impact
of TA was not seen at 18 months, suggesting that the
eﬀect of implementing this would be less certain over a
longer timescale. The OR for SSK sent, relative to con-
trols, was at the lower end of the range of results in the
meta-analysis. The apparently detrimental eﬀect of the
oﬀer of an NN was unexpected and has no obvious
explanation. It may have increased negative perceptions
of screening by appearing overbearing and encouraging
‘non-compliance’.
Self-sampling as a basis for HPV testing oﬀers the
attraction of convenience, privacy, and avoidance of a
speculum examination. It is not surprising, therefore,
that SSK sent emerged as the most eﬀective intervention,
though the insight gained in our study regarding how non-
attending women react to an SSK was unexpected.
Because our clusters were representative of the age-speci-
ﬁed female population, the ﬁndings should be generaliz-
able. Whether or not these ﬁndings in young women
would be generalizable amongst the entire age range of
cervical screening is uncertain, though it seems possible
that post-menopausal women may prefer self-sampling
to a speculum as a means of obtaining a cervical
sample. The ﬁndings suggest, however, that consideration
should be given to a wider pilot study. A detailed eco-
nomic analysis has been performed, and the cost-eﬀective-
ness results will be published separately.
The pattern of uptake seen over time has relevance for
reminders for non-attenders in an HPV primary screening
programme, which will have extended screening intervals.
Non-attendance with no recall for ﬁve or six years carries
a signiﬁcant risk compared with current recall after three
years. Our data suggest that a reminder after 18 months
may be of more value than after six, and it would be
sensible for non-attendance after three years to prompt
a further reminder.
Conclusions
This large controlled study has demonstrated that sending
SSKs and providing TA to non-attenders achieved a small
uplift in screening one year following the invitation.
The eﬀectiveness over a longer time scale and across a
wider age range warrants further study.
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